In comparison to baseline, tumor mutation landscapes on-treatment and post-treatment were generally unchanged, with the most common concurrent alterations still being TP53, PIK3CA and RB1 (Supplementary Fig. 8). The gene discussed is RB1; the disease is neoplasm.